GLP1R and type 2 diabetes mellitus: In addition, three specific GLP-1 RAs are approved and recommended in several treatment guidelines to improve established CVD or CVD risk factors in people with type 2 diabetes (Arnett et al., 2019; Dunlay et al., 2019; Buse et al., 2020; Honigberg et al., 2020; Sattar et al., 2021; American Diabetes Association Professional Practice Committee, 2022).